Das könnte abgehen....
Seite 14 von 44 Neuester Beitrag: 24.04.21 23:50 | ||||
| Eröffnet am: | 30.01.09 11:58 | von: Touwse | Anzahl Beiträge: | 2.094 |
| Neuester Beitrag: | 24.04.21 23:50 | von: Franziskasha. | Leser gesamt: | 116.408 |
| Forum: | Hot-Stocks | Leser heute: | 51 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 11 | 12 | 13 | | 15 | 16 | 17 | ... 44 > | ||||
und analysten ....was ihre show am 41.2. gezeigt hat , wurde auf der homepage auch noch nicht veröffentlicht.
Es steht punkto Zerenex nur, das sie den Antrag jetzt bei der FDA einreichen
HONG KONG, March 1, 2011 /PRNewswire via COMTEX/ -- Today, www.WorldStreetFundamentals.com released its industry report highlighting Keryx Biopharmaceuticals (KERX 3.91, -0.04, -1.01%) and Jazz Pharmaceuticals, Inc. (JAZZ 24.26, -0.37, -1.50%) . Investors from around the world are invited to view fundamental and technical analysis at www.WorldStreetFundamentals.com.
Biotech is enabling creation of new drugs at a faster pace than previous traditional pharmaceutical models. After a decade of mediocre performance the sector appears to be approaching an inflection point. Companies are much more conducive to focusing on productivity and emerging markets are expected to be back to top growth by 2013.
World Street has highlighted Keryx Biopharmaceuticals due to its recent price-movement in its historical $3.50-$4.00 value range. Several major Wall Street firms are reiterating their "buy" ratings in anticipation of potentially successful results in Keryx's two Phase III trials with the FDA, including KRX-0401 (Perifosine) and Zerenex (Ferric Citrate). To read the report on Keryx Biopharmaceuticals (KERX 3.91, -0.04, -1.01%) , visit www.WorldStreetFundamentals.com.
Jazz Pharmaceuticals, Inc. (JAZZ 24.26, -0.37, -1.50%) continues to perform well into 2011, breaking $20 resistance levels with strong volume. World Street recognizes Jazz Pharmaceuticals for its recently granted patent related to Xyrem (sodium oxybate) oral solution: "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy". The patent, number 7,851,506, became a catalyst for recent price movement and is already listed in the Orange Book (FDA's Approved Drug Products List).
To view fundamental and technical analysis on these two industry members we encourage investors to visit: www.WorldStreetFundamentals.com.
About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets around the world. Covering the top performers in the hottest sectors and providing clarity to investors around the world.
FOR INFORMATIONAL PURPOSES ONLY, NO RECOMMENDATION TO BUY OR SELL SECURITIES SHOULD BE CONSTRUED FROM THIS RELEASE. WORLD STREET HAS NO RELATIONSHIP WITH THE ABOVE MENTIONED COMPANIES AND HAS NOT BEEN COMPENSATED BY ANY THIRD-PARTY.
SOURCE World Street Fundamentals
eine sehr positive stimme also
woche sind einige webcast..bin mal gespannt, ob sich dann was gegen norden tut daily was sagst du dazu??????
March 9 (Reuters) - Keryx Biopharmaceuticals Inc:
* Brean Murray raises Keryx Biopharmaceuticals Inc price target to $10
from $8 For a summary of rating and price target changes on S&P 500 companies:
Reuters 3000Xtra users, double-click
Reuters Station users, click .1568
Reuters Plus users search on RCH/US
For a summary of rating and price target changes on non-S&P 500 companies:
Reuters 3000Xtra users, double-click
Reuters Station users, click .2102
Reuters Plus users search on RCH/US2
For a summary of rating and price target changes on Canadian companies:
Reuters 3000Xtra users, double-click
Reuters Station users, click .4899
Reuters Plus users search on RCH/CA
(Bangalore Equities Newsdesk +91 80 4135 5800; within U.S. +1 646 223 8780)
COPYRIGHT
Copyright Thomson Reuters 2011. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Wer hat es zuerst durchgelesen? ;-)
Auf der Keryx-Webseite gibt's eine firmeneigene Zusammenfassung:
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
Keryx to Host Investor Conference Call on Wednesday, March 9, 2011 at 8:30am EST
NEW YORK, March 8, 2011 /PRNewswire via COMTEX/ --
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2010.
At December 31, 2010, the Company had cash, cash equivalents, interest receivable, and investment securities of $28.5 million, as compared to $35.9 million at December 31, 2009.
The net loss for the fourth quarter ended December 31, 2010 was $5.3 million, or $0.09 per share, compared to a net loss of $4.7 million, or $0.08 per share, for the comparable quarter in 2009, representing an increase in net loss of $0.6 million. Other research and development expenses increased by $2.6 million, as compared to the fourth quarter of 2009, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs. The fourth quarter of 2009 included a $1.5 million one-time research and development expense related to a terminated early-stage pipeline product candidate, which accounts for the net increase in other research and development expenses of $1.1 million as compared to the fourth quarter of 2009.
The net loss for the year ended December 31, 2010, was $20.3 million, or $0.34 per diluted share, compared to net income of $10.5 million, or $0.21 per diluted share, for the year ended December 31, 2009. The change in net (loss) income was primarily attributable to a $21.6 million decrease in license revenue and a $3.6 million decrease in other revenue. License revenue in the year ended December 31, 2009 was related to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii) which eliminated the Company's significant ongoing obligations included in the original agreement ($18.0 million) and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009. Other revenue in the year ended December 31, 2009 was primarily related to the settlement of a dispute for $3.5 million with the former licensor of Sulonex (sulodexide), in July 2009. The change in net (loss) income was also attributable to a $6.4 million increase in other research and development expenses primarily related to increased expenses for KRX-0401 (perifosine) and Zerenex, as compared to the comparable period last year, related to the Company's ongoing Phase 3 clinical development programs.
Ron Bentsur, the Company's Chief Executive Officer, commented, "Following another very exciting year, with both of our compounds entering Phase 3 development under SPA agreements with the FDA and the announcement of positive Phase 3 data on Zerenex, we expect to leverage the momentum in 2011 with the anticipated completion of our Phase 3 metastatic colorectal study. On the financial side, we believe we are sufficiently funded to realize the value inherent in our late stage compounds, which we believe represent tremendous commercial opportunities."
Rating-Update:
New York (aktiencheck.de AG) - Die Analysten von Ladenburg Thalmann stufen die Aktie von Keryx Biopharmaceuticals (Profil) unverändert mit dem Rating "buy" ein. Das Kursziel werde von 9 USD auf 10 USD erhöht. (10.03.2011/ac/a/u)
Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
Optionen
| Boardmail an "Heron" |
Wertpapier: Keryx Biopharmaceutical |
die chancen stehen hier bestens. aeterna bekommt bereits vermarktungsmillionen in asien...perifonsine zulassung doch sehr wahrscheinlich